The effect of amphotericin B methyl ester (AME) on human immunodeficiency virus (HIV-1) was examined in vitro in cultures of H9, Molt-3 and human peripheral blood lymphocytes acutely infected with HIV. AME inactivates HIV-1 at non-cytotoxic concentrations ranging from 1O-100fL9 mr",and protects pretreated target cells from the cytopathic effects of the virus. AME inhibits the cell to cell spread of virus, as shown by the blocking of syncytia formation in Molt-3 cells, and the reduction in the level of virus expression in cultured peripheral blood leukocytes from an AIDS patient. These results suggest AME may be an effective chemotherapeutic agent in the treatment of AIDS patients, and, because of its unique mode of action may act cooperatively with other AIDS chemotherapeutics. Received 
Introduction
With the identification of human immunodeficiency virus (HIV-1) as the aetiologic agent of acquired immune deficiency syndrome (AIDS) (Gallo, 1987; Sarin, 1986) and with the knowledge that there are approximately 10 million HIV-1-infected individuals world-wide, it is important to develop therapeutic agents for the treatment of the disease. This paper reports the effect of amphotericin B methyl ester (AME) on the expression of HIV-1 in several cell lines and peripheral blood lymphocytes of an HIV-1positive patient with AIDS. HIV-1 infects the target cells by binding through the CD4 receptor on the helper/inducer subset of T lymphocytes (Dalgleish, 1984; Klatazmann et al., 1984) and recent studies show that the soluble CD4 protein can block virus infection. The virus then enters the cells and this is followed by reverse transcription and subsequent integration of the viral DNA. The immune activation of the infected cells results in virus expression and subsequent cell death (Zagury et aI., 1986) . AME is a water-soluble derivative of amphotericin B, and is much less toxic than the parent compound (Bonner et al., 1975; Kiem etal., 1976; Schaffner et aI., 1986) . It has been shown to possess antiviral activity against lipidenveloped viruses, including influenza virus (Dahlberg, J.E. et al., 13th Intersci. Conf. Antimicrob. Agents Chemother., abst. M190, 1972) , herpesvirus (Stevens et al., 1975) , rabiesvirus (Pontani, 1987) , murine leukaemia virus (Chirigos, M.A. et al., 13th Intersci. Conf. Antimicrob. Agents, Chemother., 1972) and human immunodeficiency virus (HIV-1) (Sarin, 1988; Schaffner et aI., 1986) .
HIV-1 contains a high cholesterol/phospholipid ratio in the envelope and hence drugs that selectively bind cholesterol are likely to have inhibitory effects on its infectivity (Crews et al., 1988) . The polyene macrolide group of antibiotics can bind to sterols in the membranes of cells and viruses containing a lipid envelope (Stevens et al., 1975) . Its mode of action is membrane-associated, making this antibiotic unique in terms of its inhibitory activity against HIV-1.
Results
Anti-HIV activity of AME Simultaneous addition ofAMEand HIV-1. AME was added to cultures of H9 cells in concentrations of 1-10 fL9 mr', simultaneously with virus. Figure 1 shows the composite results of eight separate experiments in which AME, at a non-cytotoxic concentration of 5 fL9 mr', significantly inhibited HIV-1 replication and the cytopathic effect of the virus. Cell viability in AME-treated Virus-infected cultures increased in a dose-dependent manner. Virus expression was greatly inhibited at the higher levels of drug, as demonstrated by the absence of p24 antigen expression. In addition, the reverse transcriptase activity was reduced from the virus control levels of >300000 c.p.m. to background levels with AME at 10 fL9 rnr', These results are typical and reproducible.
To assess the cumulative toxic effect of AME and to determine whether the continual presence of the drug might increase its antiviral activity, AME was added to cultures of H9 cells once daily during culture. AME at 1 fLg rnr' was capable of totally inhibiting the expression of virus ( Fig. 2) , as seen in the increase in the percentage of viable cells to control levels, and the virtual absence of cells expressing viral protein antigens. The reverse transcriptase (R1) activity is apparently high, but this can be attributed to the RT level of the virus inoculum and not its replication. In other subsequent experiments this background RT activity was controlled and subtracted from the RT activity in experimental cultures.
The cell to cell spread of virus can be measured by the number of syncytia formed in cultures of Molt-3 cells infected with HIV-1. Typically, these cells are much more vulnerable to the effects of the virus, and yield numerous syncytia. The results in Fig. 3 show that AME can effectively inhibit formation of syncytia. The number of syncytia decreased from> 150 in control cultures to <5 in cultures containing AME. Direct inactivation of HIV-1 by AME. To further evaluate the antiviral activity of AME, the drug was added directly to the HIV-1 inoculum before the virus was used to infect target cells. The virus was pretreated with AME at 10 and 100 fLg mr'. As shown in Table 1 , the infectivity of H1V-1 was abolished by the direct action of AME at 10 fL9 rnr', Virus was also inactivated at the higher level (1 00 fL9 rnr'), but there was a decrease in cell viability related to the toxicity of the preparation. The other parameters of virus replication (expression of p24 antigen and R1) were significantly reduced.
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Direct action on target H9 cel/s. AME can bind to membranes of uninfected target cells, thus protecting these cells from infection by the virus. This is evident from the effect of preincubating H9 cells with drug, washing the cells to remove unbound drug and then infecting the The effect of continuous addition of AME on infection of H9 cells in culture by HIV-1. AME was added to these cultures each day for a period of four days, after which the cultures were split into two portions: one was continued for a period of four days (e), and the other for eight days (.). Virus (HTLV-III/B) was added once at the start of the incubation when AME was first added. The cells were harvested and assayed for virus expression. Control cultures included H9 cells with virus only, H9 cells without virus or drug, and H9 cells with drug only (no virus).
Targets of AME in HIV-1 infection of different eel/lines 69 after which they were washed free of extracellular virus, and cultured for four days in the presence of AME. In this way, the effect of AME on virus replication in infected cells and its spread can be measured directly without the drug binding to virus before it can adsorb to the target cells. The results, shown in Fig. 4 , indicate that AME can inhibit the progression of virus infection at levels equal to those that .are effective when it is added to cultures of H9 cells simultaneously with virus. Fig. 3 . The effect of AME on syncytia formation. AME was added to cultures of Molt-3 cells simultaneously with HTLV-III/B. The cultures were harvested after four days of incubation and the number of syncytia counted for each culture. The results represent the average number of syncytia per field in duplicate cultures.
treated cells with HIV-1. Various concentrations of AME were used to pretreat the target cells. The results are shown in Table 2 . Higher concentrations of AME (50-100 [Lg ml-1 ) were necessary to protect H9 cells against infection by HIV-1 than to inhibit the infection of H9 cells directly.
To show that the protective action of AME was due to its stable binding to the target cells and not associated with residual or dissociable AME in solution, the treated cells were washed three times with phosphate-buffered saline and after each wash step the washed cells and supernatant fluid were analysed. The results showed that the protective activity of AME remains with the cell preparation. The expression of p24 antigen in the washed cell preparations remained at <1 %, in contrast to that in the virus control cultures (16%). The treated cells, after three successive washes, continued to be protected against the cytopathic effects of HIV-1. The number of Viable Cells in cultures of treated washed cells was 2.35 x 10 6 ml" compared to 1.30 x 10 6 ml-1 in the virus control and 2.60
x 10 6 mr' for the uninfected H9 control.
Activity of AME in a culture of lymphocytes from an AIDS patient. To assess the anti-HIV effect of AME in a setting more closely reflecting the clinical infectious process of HIV in vivo, peripheral blood lymphocytes from an AIDS patient known to be virus-positive (p24 antigen expression was determined by immunofluorescence) were co-cultured in the presence of phytohaemagglutinin and interleukin-2 (IL-2) with normal peripheral blood leukocytes. o o
After several weeks of mitogen-stimulated growth, the cells were divided into two sets of cultures, one of which was treated with AME. Cells from experimental and control cultures were passaged at four-day intervals, with AME being added to experimental cultures at the beginning of each passage. Normal peripheral blood lymphocytes and IL-2 were added to all cultures. Viral expression was measured by the presence of viral p24 antigen (reacting with fluorescent antibody). Virus expression was completely suppressed in cultures containing AME; in the control cultures without the drug, 10% of the cells were virus-positive.
a. AME was added to HTLV-III/B directly, and the mixture was incubated for one hour at room temperature with constant mixing. The virus/drug mixture was centrifuged and the pellet washed once with serum-free RPMI. After repelleting, the virus was dispersed in RPMI growth medium, and added to H9 cell cultures. After four days of incubation, the cells were harvested and assayed for virus infectivity. The results are the average of duplicate cultures.
Cytotoxicity ofAME in culture. To measure the cytotoxicity of AME, cultures of H9 cells were incubated in the presence of various concentrations of drug for 96 hours, after which the cells were harvested and their viability scored in terms of changes in membrane permeability. Fig. 4 . Activity of AME against HIV-1 pre-infected H9 cells. H9 cells were infected with HTLV-Ili/B in culture for 24 hours, after which they were recovered by centrifugation, washed free of extracellular virus, and resuspended in growth medium. Virus-infected cells, and control noninfected cells were cultured for four days with AME, added at the start of the culture in different doses, after which virus replication was assessed in terms of cell viability, reverse transcriptase activity and expression of viral antigens.
The threshold of discomfort (TD 50 ) of AME against H9 cells is approximately 75 J.Lg rnr', whereas it is active in inhibiting the infection of H9 cells at 5-10 J.Lg mr', well below its cytotoxic level.
Discussion
The water-soluble methyl ester derivative of amphotericin B (AME) is highly effective in inhibiting the infection of permissive lymphocytes by HIV-1 in vitro. This conclusion is based on our earlier results (Sarin, 1988; Schaffner et aI., 1986) , which are extended in this paper. The purpose of the study, reported here, was to identify the particular targets of AME in its inhibition of HIV-1 infection of permissive lymphocytes, which is a multi-stage process. The virus must bind to a specific receptor of susceptible cells (Klatzmann et aI., 1984; Zagury et al., 1986) , penetrate the cell, replicate itself, and spread the infection through its progeny or syncytia formation. HIV-1 is a lipid-enveloped virus, so AME should bind to it and conceivably inhibit its infectivity. This is indeed the case.
Direct action of AME on HIV-1, at 10 J.Lg mr", completely inactivated the virus. It remains to be determined whether or not binding of AME to the virus prevents the virus from binding to its receptor on permissive cells or whether it prevents its penetration into the cell. AME also binds to lymphocytes, and in fact acts as an immunomodulator (Blanche et al., 1977; Little et al., 1983) . It was tested, therefore, for its possible action against virus-infected cells and normal permissive cells prior to infection. The results show that AME, at non-cytotoxic levels, inhibits the replication of virus in virus-infected cells and/or its spread from infected cells to surrounding normal cells. This is clear from the results with two types of virus-infected cells: (i) H9 cells infected in culture with HIV-1 (Fig. 4) , and (ii) naturally infected peripheral blood lymphocytes from a virus-positive AIDS patient. In both cases, the expression of virus in infected cells was almost completely inhibited. In cultured peripheral blood lymphocytes the spread of infection to non-infected cells was prevented. This is further supported by our finding that AME prevents the formation of syncytia in cultures of Molt-3 cells infected with HIV-1 (Fig. 3) . The observed antiviral activity of AME is presumably the result of its binding to the membrane of Virus-infected cells, but its actual mechanism of action is unknown.
The mechanism of action of AME is unique and differs from that of drugs currently under investigation. Most of these rely on their entry into the target cell and their ability to interfere with viral replication only after the virus has infected the cells. AME offers a unique opportunity to complement the activity of these compounds by interfering with the virus at an early stage of its replicative cycle. AME can effectively neutralize virus activity without entry into the host cell.
The advantage of this can be demonstrated by the fact that AME can suppress virus expression in an AIDS patient's cultured lymphocytes and in an in vitro correlate of a clinical infection. This is evidence of the therapeutic potential of AME in treating AIDS patients. The recent report (Prakash, 1988) of the ability of amphotericin B to reduce the level of circulating HIV p24 in several AIDS patients after a single dose further supports the potential of AME in the treatment of AIDS patients. AME is equal, if not superior, to amphotericin B in terms of its antiviral activity in culture. In some viral systems AME exhibits potent antiviral activity, whereas amphotericin B is virtually inactive. Antiviral toxicity studies show that AME is much less toxic than amphotericin B (Kiem, 1976) . The pharmacological-toxicological properties of AME have been reviewed, as have the earlier clinical experiences in the treatment of deep-seated fungal infections (Schaffner, 1984) . Clinical observations of neurotoxicity appear to be related to overdosing of patients with impure preparations of AME (Hoeprich et aI., 1988). In general, AME is not metabolized and is readily excreted through the bile and the kidneys, where it poses no risk of the damage seen with amphotericin B. AME is also an effective antifungal drug and an immunomodulatory agent capable of enhancing T-cell-dependent immunity. Because of its multiple activities AME provides another approach for the treatmentt of AIDS and AID~ related complex (ARC) patients as a potent inhibitor of HIV-1 either alone or in combination with other antiviral agents or immunomodulators. This direct effect of AME on HIV-1 is consistent with the known binding of AME to sterols in the membrane of cells and certain microorganisms including fungi and lipid-enveloped viruses.
Materials and Experimental procedures

Test drug
Amphotericin B methyl ester (AME)was prepared as described by Mechlinski and Schaffner (1972) , and converted to the aspartate salt. High-pressure liquid chromatography (HPLC) analysis of the preparation showed that it contained 49.3% of the monoester AME. several related heptaene polymethylated products and less than 3% residual amphotericin B.
Cel/ cultures
The cells, H9, and Molt-3 were maintained by serial passage in RPMI medium supplemented with 20% fetal bovine serum. 2% glutamine. and 1% gentamicin. and cultured at a cell density of 5 x 10 5 viable cells per ml of culture medium.
HIV-1
HTLV-III/B stock virus was prepared from cultures of infected H9 cells. Virus was isolated from cell culture supernatants as described previously (Sarin, 1988) . In all cases. infection was initiated by incubating 5 x 10 5 cells in the presence of approximately 1000 virus particles per cell. The cultures were incubated for 4d at 3rC in a humidified atmosphere containing 5% CO2 .
Assay methods
These have been described before (Sarin, 1988) . To demonstrate the presence of replicating virus in cultures of infected cells, several parameters were utilized. (i) Syncytia formation: the average number of syncytia (multinucleated giant cells) per microscopic field was determined by direct counting. (ii) Cell viability.: this was based on trypan blue exclusion. (iii) Reverse transcriptase activity: supernatants from virus-infected cultures were assayed for the incorporation of FH]-deoxithymidine triphosphate by reverse transcriptase as a measure of viral replication. (iv) Immunofluorescent staining: infected cells were examined forthe presence of p24 viral antigen by specific staining with mouse monoclonal p24 antibody and fluorescein lsothiocyanate (FITC) labelling. The numbers of fluorescent positive cells in Targets of AME in HIV-1 infection of different eel/lines 71 several .flelds were counted, and the results expressed as percentages of the total cells in those fields.
Biologicals
Phytohaemagglutinin (Difco Labs) was added to RPMI growth medium. at a concentration of 5fL9 mr ' for the CUltivation of normal peripheral leukocytes. Interleukin-2 (IL-2) (Collaborative Research, Inc.) (10%) was added to RPMI growth medium.
Analysis of data
All assays were run in duplicate, and the data shown represent the mean value of the duplicates. The bars represent the range of the actual values. Replicate results from different experiments are extremely close, with no more than 5% fluctuation. Each individual point cannot be separately evaluated statistically but should be considered as one of a sequence of points. Together they show a typical dose response, and the overall result can be considered significant in this context.
